Here’s whether Insmed, Inc. (INSM) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.70% over 10 days); 3-month momentum positive (+13.4%); rising volume confirms the move (1.42x 30d avg). Concerns: trading below the 200-day MA (long-term downtrend). Currently 41.8% off its 52-week high. Score: +2/7.
INSM is trading below its 200-day MA ($145.50) — a key warning sign the longer-term trend is under pressure. An RSI of 66.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -3.1% compares to +20.4% for SPY (trailed the market by 23.5%). The current 41.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $9,686 today
vs. S&P 500 (SPY) — same period trailed market by 23.5%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($145.50)
✓Above 50-day MA ($107.72)
✓RSI(14) neutral zone (30–70) — currently 66.8
✗Positive return (-3.1%)
!Within 10% of period high (−41.8%)
Period Range $123.74
$90.39$212.75
RSI (14) 66.8
0 · OversoldOverbought · 100
Key Metrics
Price$123.74
Period Return-3.1%
Period High$212.75
Period Low$90.39
Drawdown−41.8%
MA-50$107.72
MA-200$145.50
RSI (14)66.8
Avg Volume (30d)3.0M
vs. SPYtrailed by 23.5%
Return Rank#727 of 1252
Trend Signals
Price is below the 200-day moving average ($145.50)
Price is above the 50-day moving average ($107.72)